Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 138531-07-4
2. Ati 01
3. Kl4 (peptide)
4. Sinapultide [usan:inn]
5. Unii-040x3ax99t
6. Kl4 Peptide
7. Rwj 45652
8. Peptide Kl4
9. Peptide Kl-4
10. Schembl180504
11. Ati-01
12. Chembl2103901
13. Dtxsid30160707
14. 040x3ax99t
15. Rwj-45652
16. Db11332
17. L-lysine, L-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-
18. L-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysyl-l-leucyl-l-leucyl-l-leucyl-l-leucyl-l-lysine
Molecular Weight | 2469.4 g/mol |
---|---|
Molecular Formula | C126H238N26O22 |
XLogP3 | 11.9 |
Hydrogen Bond Donor Count | 27 |
Hydrogen Bond Acceptor Count | 28 |
Rotatable Bond Count | 93 |
Exact Mass | 2468.83375816 g/mol |
Monoisotopic Mass | 2467.83040333 g/mol |
Topological Polar Surface Area | 775 Ų |
Heavy Atom Count | 174 |
Formal Charge | 0 |
Complexity | 4880 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 21 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Infant respiratory distress syndrome,,,.
Windtrees KL4 surfactant technology produces a synthetic surfactant that is structurally similar to human pulmonary surfactant and contains a proprietary synthetic peptide KL4 (sinapultide), cost a 21-amino acid peptide that is formulated to mimic the essential attributes of the human surfactant protein B (SP-B). This protein is one of four surfactant proteins and is the most important for the adequate function of the respiratory system. Windtree has demonstrated in pre-clinical studies that KL4 surfactant may possess certain other beneficial properties, including alteration of the inflammatory process, antimicrobial properties as well as non-immunogenicity.
Absorption
Administered directly to the lung, where biophysical effects occur at the terminal airways and alveolar surface. No human pharmacokinetic studies have been done to characterize the absorption, distribution, metabolism, or elimination of this drug.
Endogenous pulmonary surfactant lowers surface tension at the air-liquid interface of the alveolar surfaces during respiration and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants results in RDS. Surfaxin, the drug in which this protein is included, compensates for the deficiency of surfactant and restores surface activity to the lungs of these infants. To explore the mechanisms of protection that this sinapultide offers against RDS, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was studied. Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, the results that showed KL(4)-surfactant, blocked neutrophil influx into alveoli and thus prevented lung injury. Additionally, in vitro assays demonstrated KL(4)-surfactant decreased neutrophil transmigration at the endothelial cell level. KL(4)-surfactant diminished inflammation and lung permeability when compared with controls in both mouse models of lung injury. Evidence suggests the anti-inflammatory mechanism of the KL(4)-peptide is achieved through inhibition of PMN transmigration through the endothelium.
Related Excipient Companies
Excipients by Applications
ABOUT THIS PAGE
34
PharmaCompass offers a list of Sinapultide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sinapultide manufacturer or Sinapultide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sinapultide manufacturer or Sinapultide supplier.
PharmaCompass also assists you with knowing the Sinapultide API Price utilized in the formulation of products. Sinapultide API Price is not always fixed or binding as the Sinapultide Price is obtained through a variety of data sources. The Sinapultide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Kl4 peptide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Kl4 peptide, including repackagers and relabelers. The FDA regulates Kl4 peptide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Kl4 peptide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Kl4 peptide supplier is an individual or a company that provides Kl4 peptide active pharmaceutical ingredient (API) or Kl4 peptide finished formulations upon request. The Kl4 peptide suppliers may include Kl4 peptide API manufacturers, exporters, distributors and traders.
click here to find a list of Kl4 peptide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Kl4 peptide DMF (Drug Master File) is a document detailing the whole manufacturing process of Kl4 peptide active pharmaceutical ingredient (API) in detail. Different forms of Kl4 peptide DMFs exist exist since differing nations have different regulations, such as Kl4 peptide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Kl4 peptide DMF submitted to regulatory agencies in the US is known as a USDMF. Kl4 peptide USDMF includes data on Kl4 peptide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Kl4 peptide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Kl4 peptide suppliers with USDMF on PharmaCompass.
Kl4 peptide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Kl4 peptide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Kl4 peptide GMP manufacturer or Kl4 peptide GMP API supplier for your needs.
A Kl4 peptide CoA (Certificate of Analysis) is a formal document that attests to Kl4 peptide's compliance with Kl4 peptide specifications and serves as a tool for batch-level quality control.
Kl4 peptide CoA mostly includes findings from lab analyses of a specific batch. For each Kl4 peptide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Kl4 peptide may be tested according to a variety of international standards, such as European Pharmacopoeia (Kl4 peptide EP), Kl4 peptide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Kl4 peptide USP).